Triple Negative Breast Cancer - Epidemiology Forecast - 2032

Key Highlights

• Breast cancer is a genetically and clinically heterogeneous disease with multiple subtypes. The classification of these subtypes has evolved over the years. The most common and widely accepted classification of breast cancer is from an immunohistochemical perspective, based on the expression of the following hormone receptors: estrogen (ER), progesterone (PR), and human epidermal growth factor (HER2).
• Triple-negative breast cancer (TNBC) accounts for 15-20% of incident breast cancers and is the only breast cancer (BC) subtype lacking targeted treatments. Using clinical assays, TNBC is human epidermal growth factor receptor 2 (HER2) negative and has < 1% expression of estrogen receptors (ER) and progesterone receptors (PR) by immunostaining. It is a biologically aggressive tumor characterized by moderate/high grade and highly proliferative cancer cells, which, together with limited treatment options, leads to the poorest prognosis among breast cancer subtypes.
• The risk factors of TNBC have been bifurcated into non-modifiable and modifiable risk factors. The non-modifiable risk factors include age, sex, genetic mutations, genetic history, breast tissue density etc. The modifiable risk factors include drugs, BMI, insufficient vitamin supplements, exposure to chemicals and drugs etc.
• The diagnostic process starts with noticing and evaluating the signs and symptoms, but the diagnosis is not based on any specific symptoms. Hence, post-assessment of these symptoms, imaging tests, and a biopsy confirmed a breast cancer diagnosis. Once a breast cancer diagnosis has been made, the cells from the biopsy are checked for estrogen, progesterone, and HER2 receptors to determine a person's breast cancer subtype.
• Cells that lack all the three receptors are classified as triple-negative breast cancer. Using gene expression profiles, TNBC can be further classified as basal-like or having specific mutations in genetic susceptibility genes such as BRCA1/2.
• Regarding the epidemiology of TNBC, in 2022, it was found that the United States accounted for ~45% of the total incident cases of Breast Cancer in the 7MM. Therefore, the US accounted for the largest share of incident population of TNBC in the 7MM.
• Among the EU4 countries, the least number of incident cases of TNBC were found in Spain followed by Italy, i.e., ~5,100 and ~8,300 cases in the year 2022. These cases are expected to increase by 2032.
• The total incident cases of TNBC in the UK were found to be ~8,500 in 2022, which comes out to be around 10% of the total incident cases of TNBC in the 7MM.

This “Triple Negative Breast Cancer (TNBC) - Epidemiology Forecast - 2032” report delivers an in-depth understanding of TNBC disease, diagnosis, stages, and historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032
Triple Negative Breast Cancer (TNBC) Understanding and Diagnostic Algorithm

Triple Negative Breast Cancer (TNBC) Overview

Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of fundamentally different diseases with different histologic, genomic, and immunologic profiles, which are aggregated under this term because of their lack of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression. Massively parallel sequencing and other omics technologies have demonstrated the level of heterogeneity in TNBCs and shed light on the pathogenesis of this therapeutically challenging entity in breast cancer.

Further details related to overview are provided in the report…

Triple Negative Breast Cancer (TNBC) Diagnosis

Confirming any breast cancer diagnosis is the first step toward developing an appropriate treatment plan. One implication of a triple negative test result is that the presence of these hormones will not stimulate cancer growth. Another is that traditional breast cancer hormonal therapy, such as the use of tamoxifen or aromatase inhibitors, is ineffective for treating these cancers. Surgery, radiation therapy and/or chemotherapy may still be recommended to treat triple-negative breast cancer, and researchers are continually investigating new medications and therapies for this purpose.

Most breast cancers are detected before a woman shows symptoms through regular breast cancer screening such as mammography. However, triple-negative breast cancer is more likely to occur in younger women (less than 40 years old) before they reach screening age; hence, the diagnostic process of TNBC relies on the patient noticing its signs and symptoms. Women of any age must be familiar with their breasts to spot changes, such as a hard lump.

Further details related to diagnosis are provided in the report…

Triple Negative Breast cancer (TNBC) Epidemiology

The TNBC epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Breast Cancer, Total Incident Cases of Triple Negative Breast Cancer (TNBC), Subtype-specific Cases of TNBC, Gene Mutation-specific Cases of TNBC, Stage-specific Cases of TNBC, Age-specific Cases of TNBC, and Linewise Treated Cases of TNBC in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2019 to 2032.

• The United States accounted for ~43,200 incident cases of TNBC in 2022, which is projected to increase during the forecast period (2023-2032).
• The total incident cases of TNBC in EU4 and the UK were ~42,000 in 2022. The cases will increase during the forecast period (2023-2032).
• The total incident cases of TNBC in Japan were found to be ~14,900 in 2022, which are expected to increase during the forecast period (2023-2032).
• Germany accounted for the highest number of total incident cases of TNBC in EU4 and the UK, which were ~10% of the total incident cases in the 7MM.

Scope of the Report

• The report covers a segment of executive summary, and a descriptive overview of Triple Negative Breast Cancer (TNBC), explaining its intrinsic molecular subtypes, characteristics of tumor microenvironment, potential risk factors, clinical presentation, and diagnosis.
• Comprehensive insight into the country-wise epidemiology segments and forecasts, the future growth potential of diagnosis rate, and insights on disease progression have been provided.
• Patient stratification based on immunohistochemical expression is an inclusion
• A detailed review of different staging present in Triple Negative Breast Cancer (TNBC)

Triple negative Breast Cancer (TNBC) Report Insights

• TNBC Patient Population
• Subtype-specific, Gene Mutation-specific, Age-specific, and Stage-specific Distribution in TNBC
• Country-wise Epidemiology Distribution

Triple negative Breast Cancer (TNBC) Report Key Strengths

• 10 year Forecast
• The 7MM Coverage
• Triple negative Breast Cancer (TNBC) Epidemiology Segmentation

Triple negative Breast Cancer (TNBC) Report Assessment

• Epidemiology Segmentation
• Current Diagnostic Practices

Key Questions Answered

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of TNBC? What will be the growth opportunities across the 7MM with respect to the patient population of TNBC?
• What is the historical and forecasted TNBC patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Which Age group is the largest contributor to the TNBC patient pool?
• Which Stage has the most number of cases of TNBC in the 7MM?

Reasons to Buy

• Insights on disease burden, details regarding diagnosis, stages, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the change in TNBC cases in varying geographies over the coming years.
• Detailed overview on subtype-specific, gene mutation-specific, age-specific, and stage-specific distribution in TNBC is included.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the drug treatment-eligible patient pool including the progressed and recurrent patients from early stage to late stage.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.